| Objective: To investigate the effects of anlotinib combined with sintilimab on serum angiogenesis factors, tumor markers, platelet/lymphocyte ratio (PLR), neutrophil/lymphocyte ratio (NLR) and lymphocyte/monocyte ratio (LMR) in patients with advanced non-small cell lung cancer (NSCLC). Methods: According to the random number table method, 84 patients with advanced NSCLC were divided into control group (42 cases, treated with anlotinib) and study group (42 cases, treated with sintilizumab combined with anlotinib). The efficacy, serum tumor markers [carbohydrate antigen 125 (CA125) and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), carcinoembryonic antigen (CEA)], angiogenesis factors [vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF)], NLR, PLR, LMR were compared between two groups, and the occurrence of adverse reactions during treatment was observed. Results: Compared with control group after treatment, the objective remission rate, disease control rate and LMR in study group were higher, and VEGF, bFGF, CA125, CYFRA21-1, CEA, NLR and PLR were lower (P<0.05). There was no difference in the total incidence of adverse reactions between two groups (P>0.05). Conclusion: Sintilimab combined with anlotinib in the treatment of advanced NSCLC patients, which can significantly reduce the level of tumor markers, inhibit NSCLC angiogenesis, and reduce inflammatory response. |
